0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Clinical Sciences |

A Study of Iridectomy Histopathologic Features of Latanoprost- andNon–Latanoprost-Treated Patients FREE

Daniel M. Albert, MD, MS; Ronald E. Gangnon, PhD; Michele L. Zimbric, BS; Christine M. Damico, BS; Marian R. Fisher, PhD; Joel Gleiser, MD; Hans E. Grossniklaus, MD; W. Richard Green, MD
[+] Author Affiliations

Author Affiliations: Department of Ophthalmologyand Visual Sciences (Drs Albert and Gleiser and Mss Zimbric and Damico) andDepartment of Biostatistics and Medical Informatics (Drs Gangnon and Fisher),University of Wisconsin Medical School, Madison; Department of Ophthalmology,Emory University, Atlanta, Ga (Dr Grossniklaus); and Department of Ophthalmology,The Johns Hopkins University, Baltimore, Md (Dr Green).


Arch Ophthalmol. 2004;122(11):1680-1685. doi:10.1001/archopht.122.11.1680.
Text Size: A A A
Published online

Objectives  To examine the histopathologic features of iridectomy specimens frompatients undergoing glaucoma surgery and to compare histologic abnormalitiesin a group of patients with a history of latanoprost therapy with those ina group of patients who had no history of prostaglandin therapy (controls).

Methods  Iridectomy specimens and patient history forms were submitted to thecentral Latanoprost Pathology Center. These were independently examined by3 ophthalmic pathologists in a masked fashion. Specimens were evaluated formalignant, premalignant, and other changes including differences in levelsof pigmentation, degrees of cellularity, inflammation, vascular abnormalities,and changes in the iris pigment epithelium.

Results  Specimens were received from 449 patients with a history of latanoprosttreatment and 142 patients who had no history of treatment with latanoprostor other prostaglandin analogues. No evidence of malignant or premalignantchanges was found. In latanoprost-treated irides, the prevalence of iris freckleswas higher (P = .001) than in control irides,as was the combined number of stromal fibroblasts and melanocytes (P<.001). In a subgroup of specimens received through June 2002,there was no significant difference in mean melanocyte counts (P=.35) obtained by immunohistochemical staining techniques betweenthe latanoprost-treated and control groups.

Conclusions  These findings support previous studies indicating that latanoprost-inducedeye color changes are due to an increased amount of melanin within the irisstromal melanocytes. The increased numbers of freckles may be a focal manifestationof this effect.

Figures in this Article

New glaucoma drugs including latanoprost, isopropyl unoprostone, travoprost,and bimatoprost are associated with increased pigmentation of the iris insome patients.1 Our knowledge of this phenomenonis based primarily on clinical observations, with relatively limited histopathologicinvestigation.2,3 This study wasdesigned to evaluate, in a systematic manner, key histopathologic findingsin iris specimens from patients undergoing glaucoma surgery and to comparethe results in groups defined by a history of latanoprost therapy or no historyof therapy with latanoprost or any prostaglandin analogues. Assessments ofmalignant or premalignant changes including the presence of melanoma, increasedcell number, and mitotic figures were recorded. Other characteristics evaluatedincluded the degree of pigmentation of the anterior border layer and stroma,inflammation, abnormalities of the stromal blood vessels, and pigment epithelialchanges. This is the first large histopathologic study to address the effectsof latanoprost on the human iris, including the safety aspects of latanoprost-inducediris pigmentation.

Iris specimens, obtained at the time of iridectomy during glaucoma surgery,were received in 10% neutral-buffered formalin at the Latanoprost PathologyCenter (LPC) and labeled by the LPC coordinator with a unique study accessionnumber. The formalin-fixed tissue specimens were processed overnight on anautomated tissue processor, embedded in paraffin, serially sectioned at 5 μm,and mounted onto treated slides. The first 3 slides were stained with hematoxylin-eosin,the next 3 slides were bleached with potassium permanganate prior to stainingwith hematoxylin-eosin, and the following 7 slides were left unstained. Allslides were labeled with the unique study accession number assigned to thespecimen. If any tissue remained after sectioning, the paraffin block wasarchived.

Sets of microscopic slides (1 hematoxylin-eosin slide, 1 bleached hematoxylin-eosinslide, and 1 unstained slide) were sent to 3 reviewing pathologists (D.M.A.,H.E.G., and W.R.G.) who examined the set independently and with no knowledgeof therapy history. They completed the accompanying pathology grading form,including an assessment of the quality of the specimens, their location, andtheir orientation. These forms were returned to the LPC coordinator, who completeda composite grading form using specific rules for combining data from the3 grading forms.

An iris freckle (ephelis) was identified by the pathologists as a focalarea of increased pigmentation in the anterior border layer melanocytes withoutan increased number of melanocytes.4 This isconsistent with the general definition of an iris freckle in the field ofeye pathology. Using all specimens received by June 2002 and the techniquespreviously described,5 1 of the unstained slideswas stained with S100a and fluorescein isothiocyanate. This stained slidewas examined by a single reviewer (in the laboratory of D.M.A.) who was maskedto treatment history and identified melanocytes and other cells (fibroblastsand clump cells) by their staining characteristics, counted them, and enteredthe counts into a spreadsheet. Specimens were adjudicated using a protocolformulated by the 3 pathologists prior to the beginning of the study.

The patient history form accompanying the specimen included iris color(blue, hazel, or brown); type of glaucoma; ocular history; type of surgery;treatment history, including the start of medical treatment; medication history,including specific medications used; duration of latanoprost therapy (<3months, 3 months to 3 years, or >3 years); other glaucoma medications used;and presence or absence of increased pigmentation after glaucoma medication.The latanoprost group was defined by a history of latanoprost therapy, andthe control group was defined by no history of therapy with latanoprost orany other prostaglandin analogue.

After review by the LPC coordinator, the patient history form and thecomposite grading form, each identified only by the unique accession number,were sent to the Statistical Data Analysis Center (Department of Biostatisticsand Medical Informatics, University of Wisconsin, Madison) for data entry(Oracle database; Oracle, Redwood Shores, Calif) and statistical analysis.The numbers of melanocytes and other cells from the subset of specimens weretransferred separately from the laboratory for their inclusion in this article.This study received institutional review board approval from the Universityof Wisconsin Health Sciences Human Subjects Committee.

Comparisons of groups were based on the Wilcoxon rank sum test for continuousand ordinal variables and the Pearson χ2 test for categoricalvariables. Analyses were performed using analysis of variance models for continuousand ordinal variables and logistic regression models for dichotomous variables,which included sex and iris color as covariates. Statistical significancewas set at P<.05. No formal adjustment for multiplecomparisons was used.

Between September 1998 and January 2003, 591 iris specimens were receivedat the LPC through the cooperation of 41 glaucoma surgeons and 22 centers,listed in Table 1. Specimens were receivedfrom 449 patients with a history of latanoprost treatment and 142 patientswho had no history of treatment with latanoprost or other prostaglandin analogues.The duration of latanoprost treatment was recorded for 346 (77%) of the 449patients in the latanoprost group; 57 used latanoprost for less than 3 months,247 for 3 months to 3 years, and 42 for more than 3 years. Table 2 summarizes, by treatment group, relevant information fromthe patient history form and the year of completion of the pathology gradingform. Race and ethnicity, iris color, type of glaucoma, and ocular historywere statistically similar for the latanoprost and control groups; however,there were more women in the control group compared with the latanoprost group(P = .01). With regard to the year of completionof the pathology grading form, there was a statistically significant difference(P<.001) in the distribution of specimens by treatmentgroup.

Table Graphic Jump LocationTable 1. Surgeons and Centers Contributing Iris Specimens
Table Graphic Jump LocationTable 2. Patient History Forms Summary*

Evaluation of the composite pathology grading forms indicated that thelatanoprost and control groups were comparable in terms of quality, location,and orientation of the iridectomy specimens (data not shown). All specimenswere obtained from the peripheral iris.

No melanomas were reported on the pathology grading form in either thelatanoprost or control group (data not shown). No statistically significantdifferences in the presence of nevi were noted either in all irides or inblue, hazel, or brown irides (Figure 1).There was, however, a statistically significant difference in the presenceof freckles in the latanoprost group compared with the control group in allirides (P = .001) and in the hazel (P = .01) and brown (P<.001)irides (Figure 2). This difference remainedstatistically significant in multivariable logistic regression models, whichincluded sex and iris color (P = .009).

Place holder to copy figure label and caption
Figure 1.

Proportion of specimens with neviby treatment group for all irides and for subgroup based on iris color.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Proportion of specimens with frecklesby treatment group for all irides and for subgroups based on iris color.

Graphic Jump Location

There was a statistically significant difference between treatment groupsin the number of combined stromal fibroblasts and melanocytes in all irides(P<.001) and in the brown irides (P<.001). In analyses by sex, there was no statistically significantdifference between groups in the number of stromal fibroblasts and melanocytesin the irides of all men (P = .24) or inthe irides of brown-eyed men (P = .32);there were statistically significant differences between groups in the iridesof all women (P<.001) and in the irides of brown-eyedwomen (P<.001). (Table 3).

Table Graphic Jump LocationTable 3. Grading Form for Stromal Fibroblasts and Melanocytes in theIrides*

No statistically significant differences in the degree of pigmentationin the melanocytes of the anterior border layer or stroma, in the mean thickness,or in many stromal features were noted between the latanoprost and controlgroups (Table 4). Free pigment granulesin the stroma (P = .05) were not statisticallysignificantly different; rubeosis, although rare, was statistically significantlydifferent (P = .002) (Table 4). The proportion of specimens determined to have a normaliris did not differ between the 2 groups (data not shown).

Table Graphic Jump LocationTable 4. Pathology Grading Form Summary*

Prior to iridectomy, 21 patients were reported to have darkening ofthe iris. All of these patients had received latanoprost treatment. In 6 cases,there was photographic documentation of the darkening. Data from patientswith clinically observed darkening of the iris were included with data fromother latanoprost-treated patients without darkening. No histopathologic abnormalitieswere seen in these specimens. It is presumed that subclinical or unnoticedeye color changes occurred in additional patients.

Using the subset of specimens received by June 2002, no statisticallysignificant differences in melanocyte counts were noted. However, there wasa statistically significant difference in other cell counts (fibroblasts andclump cells) between the latanoprost and control groups for all irides (P = .005; n = 371), brown irides (P = .02; n = 182), and men with blueirides (P = .03; n = 56) (Table 5).

Table Graphic Jump LocationTable 5. Melanocyte and Other Cell Counts for Irides*

Differences in the iris color of normal eyes are the result of variableamounts of melanin granules within a constant number of melanocytes in thesuperficial stroma of the iris.58 Irismelanocytes seem to reach their genetically determined amount of melanin inearly childhood, and their melanin content usually remains constant in adulthood.Iris color, however, can be affected by a variety of ocular disorders.9

Latanoprost, a phenyl-substituted analogue of prostaglandin F, is effective for lowering intraocular pressure. In early trials inthe United States, United Kingdom, and Scandinavia, it was associated withincreased melanogenesis in the irides of patients treated in clinical trials.10 Typically this change was manifested by a concentricincrease in iris pigmentation appearing after about 6 months of treatment.10 The incidence of increased pigmentation is apparentlyrelated to the color of the iris and has been reported to range from 5% to70%.11,12 More recently, otherprostaglandin analogues introduced for the treatment of glaucoma have beenassociated with increased pigmentation of the iris in some individuals.1 Most of the data regarding this phenomenon involvelatanoprost, which was the first prostaglandin analogue available for thetreatment of glaucoma.

In vitro studies in which human iris tissue or melanocyte cultures wereincubated with latanoprost indicate that the iris darkening associated withlatanoprost treatment is caused by the induction of tyrosinase expression.1316 Inan additional in vitro study, Dutkiewicz et al17 demonstratedthat latanoprost induced tyrosinase activity but did not increase the mitoticindex in a panel of human uveal and cutaneous melanoma cell lines. That studyalso suggested that the adverse effect of latanoprost on in vivo iris pigmentationdid not result from increased cell division but from elevated tyrosinase activity.

The cynomolgus monkey has been described as an effective animal modelfor studying the increased pigmentation of the iris with latanoprost treatment.10,18,19 Darkening of theiris was noted after about 2 months of treatment, with latanoprost inducingincreased pigmentation in sympathectomized eyes. Nevi and freckles on theiris conjunctiva or eyelids were not affected. The authors concluded thatlatanoprost treatment increased the normal low melanin synthesis in the iridialmelanocytes of the cynomolgus monkey. In latanoprost-treated eyes, the amountof eumelanin increased from 3- to 7-fold, whereas the variation of pheomelanindid not exceed 25%.20

Zhan et al21 used Dutch-belted rabbitsfollowing unilateral superior cervical ganglionectomy as an experimental modelfor studying prostaglandin-induced iris color darkening. These investigatorsdemonstrated that sympathetic innervation is required for age-related physiologicdarkening of iris color and that prostoglandins may compensate for sympatheticdenervation to produce the darkening.

Individual case reports and small series of iris specimens studied histopathologicallyfollowing darkening from latanoprost treatment have been reported.2,3,2224 Theselight and electron microscopic studies indicate that latanoprost-induced eyecolor change is due to an increased amount of melanin within the iris stromalmelanocytes rather than any increase in melanocyte number.

In our study, no evidence of malignant or premalignant changes was observedin either group based on the absence of melanomas, atypical nevi, cells withan atypical appearance, or increased numbers of mitotic figures. There wasan increased prevalence of freckles in the latanoprost-treated group. We suggestthat the increased number of freckles is a manifestation of focal increasedtyrosinase expression and that the same pathogenesis exists for the more diffusedarkening. An extreme of this change may be the latanoprost-associated, diffuse,uniform dark velvet-brown appearance simulating a diffuse iris melanoma, asdescribed by Tsai et al.2 We do not believethat the increase in iris freckles has malignant potential or can lead toany adverse clinical effect on the eye.

There was a statistically significant increase in the number of combinedstromal melanocytes and fibroblasts, most strongly evident in brown-eyed women.It should be noted that with the hematoxylin-eosin staining used for thisstudy, stromal melanocytes and fibroblasts cannot be reliably differentiated.Because of this, immunohistochemical staining was performed for the subsetof specimens received by June 2002, and no statistically significant differencein melanocyte count was seen in all irides or any subgroup. The combined stromaland fibroblast increase noted in the hematoxylin-eosin–stained slidesappears to be due to an excess of fibroblasts and/or clump cells but not melanocytes.

Prostaglandin F as well as prostaglandins E1 and E2 has been shown to act as an extracellular factorto regulate cell proliferation.25 ProstaglandinF stimulated DNA synthesis and cell proliferation in quiescentSwiss mouse 3T3 cell cultures25,26 andin 1 of 2 clones of 3T3 cells from the National Institutes of Health (Bethesda,Md).26 In addition, prostaglandin F can modulate the growth and differentiation of corneal epithelial cellscultured in vitro. Consequently, it is not surprising that an increase inthe number of iris fibroblasts and/or clump cells occurs in some latanoprost-treatedeyes.27

In summary, our results are consistent with previous findings that latanoprost-inducedeye color change is due to an increased amount of melanin within the irisstromal melanocytes and does not involve an increase in melanocyte number.Further examination of several histopathologic characteristics, as noted previously,shows no adverse histopathologic effects in latanoprost-treated irides ascompared with controls.

Correspondence: Daniel M. Albert, MD, MS,Department of Ophthalmology and Visual Sciences, F4/344 Clinical Science Center,600 Highland Ave, Madison WI 53792-3284 (dalbert@wisc.edu).

Submitted for Publication: July 17, 2003; finalrevision received January 26, 2004; accepted April 21, 2004.

Financial Disclosure: None.

Funding/Support: This study was supported bya grant from Pharmacia Corporation, a Pfizer, Inc, company (New York, NY).

Acknowledgment: We thank Kirsten L. Hope, BA,for her diligent effort as an editor.

Stjernschantz  JWAlbert  DMHu  DDrago  FWistrand  PJ Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol 2002;47S162- S175
PubMed Link to Article
Tsai  JCSivak-Callcott  JAHaik  BGZhang  JMcLean  IW Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologicreport. J Glaucoma 2001;10411- 413
PubMed Link to Article
Grierson  IPfeiffer  NCracknell  KPAppleton  P Histology and fine structure of the iris and outflow system followinglatanoprost therapy. Surv Ophthalmol 2002;47S176- S184
PubMed Link to Article
Yanoff  MFine  BS Ocular Pathology: A Text and Atlas. 2nd Philadelphia, Pa Harper & Row Publishers1982;822
Wilkerson  CLSyed  NSFisher  MRRobinson  NLWallow  IHAlbert  DM Melanocytes and iris color: light microscopic findings. Arch Ophthalmol 1996;114437- 442
PubMed Link to Article
Eagle  RC  Jr Iris pigmentation and pigmented lesions: an ultrastructural study. Trans Am Ophthalmol Soc 1988;86581- 687
PubMed
Imesch  PDBindley  CDKhademian  Z  et al.  Melanocytes and iris color: electron microscopic findings. Arch Ophthalmol 1996;114443- 447
PubMed Link to Article
Albert  DMGreen  WRZimbric  ML  et al.  Iris melanocyte numbers in Asian, African-American, and Caucasian irides. Trans Am Ophthalmol Soc 2003;101217- 222
PubMed
Imesch  PDWallow  IHAlbert  DM The color of the human eye: a review of the morphologic correlatesand of some conditions that affect iridial pigmentation. Surv Ophthalmol 1997;41S117- S123
PubMed Link to Article
Wistrand  PJStjernschantz  JOlsson  K The incidence and time-course of latanoprost-induced iridial pigmentationas a function of eye color. Surv Ophthalmol 1997;41 ((suppl 2)) S129- S138
PubMed Link to Article
Teus  MAArranz-Marquez  ELucea-Suescun  P Incidence of iris colour change in latanoprost treated eyes. Br J Ophthalmol 2002;861085- 1088
PubMed Link to Article
Camras  CBWax  MBRitch  R  et al.  Latanoprost treatment for glaucoma: effects of treating for 1 yearand of switching from timolol. Am J Ophthalmol 1998;126390- 399
PubMed Link to Article
Lindsey  JDJones  HLHewitt  EGAngert  MWeinreb  RN Induction of tyrosinase gene transcription in human iris organ culturesexposed to latanoprost. Arch Ophthalmol 2001;119853- 860
PubMed Link to Article
Drago  FMarino  ALa Manna  C Alpha-methyl-p-tyrosine inhibits latanoprost-induced melanogenesisin vitro. Exp Eye Res 1999;6885- 90
PubMed Link to Article
Hu  D-NStjernschantz  JMcCormick  SA Effect of prostaglandins A2E, E1,F2αand latanoprost on cultured human iridial melanocytes. Exp Eye Res 2000;70113- 120
PubMed Link to Article
Stjernschantz  JOcklind  AWentzel  PLake  SHu  DN Latanoprost-induced increase of tyrosinase transcription in iridialmelanocytes. Acta Ophthalmol Scand 2000;78618- 622
PubMed Link to Article
Dutkiewicz  RAlbert  DMLevin  LA Effects of latanoprost on tyrosinase activity and mitotic index ofcultured melanoma lines. Exp Eye Res 2000;70563- 569
PubMed Link to Article
Lindquist  NGLarsson  BSStjernschantz  J Increased pigmentation of iridial melanocytes in primates induced bya prostaglandin analogue. Exp Eye Res 1999;69431- 436
PubMed Link to Article
Selen  GStjernschantz  JResul  B Prostoglandin-induced iridial pigmentation in primates. Surv Ophthalmol 1997;41 ((suppl 2)) S125- S128
PubMed Link to Article
Prota  GVincensi  MRMapolitano  ASelen  GStjernschantz  J Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgusmonkeys. Pigment Cell Res 2000;13147- 150
PubMed Link to Article
Zhan  GLToris  CBCamras  CBWang  YLBito  LZ Prostaglandin-induced iris color darkening: an experimental model. Arch Ophthalmol 1998;1161065- 1068
PubMed Link to Article
Grierson  ILee  WRAlbert  DM The fine structure of an iridectomy specimen from a patient with latanoprost-inducedeye color change. Arch Ophthalmol 1999;117394- 396
PubMed Link to Article
Grierson  ICracknell  KPPfeiffer  N The iris after prostanoid treatment. Curr Opin Ophthalmol 2001;12112- 118
PubMed Link to Article
Pfeiffer  NGrierson  IGoldsmith  HHochgesand  DWinkgen-Bohres  AAppleton  P Histological effects in the iris after 3 months of latanoprost therapy:the Mainz 1 study. Arch Ophthalmol 2001;119191- 196
PubMed
De Asua  LJClingan  DRudland  PS Initiation of cell proliferation in culture mouse fibroblasts by prostaglandinF2alpha. Proc Natl Acad Sci U S A 1975;722724- 2728
PubMed Link to Article
Black  FMWakelam  MJ Activation of inositol phospholipid breakdown by prostaglandin F2 alphawithout any stimulation of proliferation in quiescent NIH-3T3 fibroblasts. Biochem J 1990;266661- 667
PubMed
Conconi  MTSpinazzi  RTommasini  MLimoli  AParnigotto  PP Prostaglandin F2 alpha can modulate the growth and the differentiationof bovine corneal epithelial cells cultured in vitro. Ann Anat 2001;183567- 573
PubMed Link to Article

Figures

Place holder to copy figure label and caption
Figure 1.

Proportion of specimens with neviby treatment group for all irides and for subgroup based on iris color.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.

Proportion of specimens with frecklesby treatment group for all irides and for subgroups based on iris color.

Graphic Jump Location

Tables

Table Graphic Jump LocationTable 1. Surgeons and Centers Contributing Iris Specimens
Table Graphic Jump LocationTable 2. Patient History Forms Summary*
Table Graphic Jump LocationTable 3. Grading Form for Stromal Fibroblasts and Melanocytes in theIrides*
Table Graphic Jump LocationTable 4. Pathology Grading Form Summary*
Table Graphic Jump LocationTable 5. Melanocyte and Other Cell Counts for Irides*

References

Stjernschantz  JWAlbert  DMHu  DDrago  FWistrand  PJ Mechanism and clinical significance of prostaglandin-induced iris pigmentation. Surv Ophthalmol 2002;47S162- S175
PubMed Link to Article
Tsai  JCSivak-Callcott  JAHaik  BGZhang  JMcLean  IW Latanoprost-induced iris heterochromia and open-angle glaucoma: a clinicopathologicreport. J Glaucoma 2001;10411- 413
PubMed Link to Article
Grierson  IPfeiffer  NCracknell  KPAppleton  P Histology and fine structure of the iris and outflow system followinglatanoprost therapy. Surv Ophthalmol 2002;47S176- S184
PubMed Link to Article
Yanoff  MFine  BS Ocular Pathology: A Text and Atlas. 2nd Philadelphia, Pa Harper & Row Publishers1982;822
Wilkerson  CLSyed  NSFisher  MRRobinson  NLWallow  IHAlbert  DM Melanocytes and iris color: light microscopic findings. Arch Ophthalmol 1996;114437- 442
PubMed Link to Article
Eagle  RC  Jr Iris pigmentation and pigmented lesions: an ultrastructural study. Trans Am Ophthalmol Soc 1988;86581- 687
PubMed
Imesch  PDBindley  CDKhademian  Z  et al.  Melanocytes and iris color: electron microscopic findings. Arch Ophthalmol 1996;114443- 447
PubMed Link to Article
Albert  DMGreen  WRZimbric  ML  et al.  Iris melanocyte numbers in Asian, African-American, and Caucasian irides. Trans Am Ophthalmol Soc 2003;101217- 222
PubMed
Imesch  PDWallow  IHAlbert  DM The color of the human eye: a review of the morphologic correlatesand of some conditions that affect iridial pigmentation. Surv Ophthalmol 1997;41S117- S123
PubMed Link to Article
Wistrand  PJStjernschantz  JOlsson  K The incidence and time-course of latanoprost-induced iridial pigmentationas a function of eye color. Surv Ophthalmol 1997;41 ((suppl 2)) S129- S138
PubMed Link to Article
Teus  MAArranz-Marquez  ELucea-Suescun  P Incidence of iris colour change in latanoprost treated eyes. Br J Ophthalmol 2002;861085- 1088
PubMed Link to Article
Camras  CBWax  MBRitch  R  et al.  Latanoprost treatment for glaucoma: effects of treating for 1 yearand of switching from timolol. Am J Ophthalmol 1998;126390- 399
PubMed Link to Article
Lindsey  JDJones  HLHewitt  EGAngert  MWeinreb  RN Induction of tyrosinase gene transcription in human iris organ culturesexposed to latanoprost. Arch Ophthalmol 2001;119853- 860
PubMed Link to Article
Drago  FMarino  ALa Manna  C Alpha-methyl-p-tyrosine inhibits latanoprost-induced melanogenesisin vitro. Exp Eye Res 1999;6885- 90
PubMed Link to Article
Hu  D-NStjernschantz  JMcCormick  SA Effect of prostaglandins A2E, E1,F2αand latanoprost on cultured human iridial melanocytes. Exp Eye Res 2000;70113- 120
PubMed Link to Article
Stjernschantz  JOcklind  AWentzel  PLake  SHu  DN Latanoprost-induced increase of tyrosinase transcription in iridialmelanocytes. Acta Ophthalmol Scand 2000;78618- 622
PubMed Link to Article
Dutkiewicz  RAlbert  DMLevin  LA Effects of latanoprost on tyrosinase activity and mitotic index ofcultured melanoma lines. Exp Eye Res 2000;70563- 569
PubMed Link to Article
Lindquist  NGLarsson  BSStjernschantz  J Increased pigmentation of iridial melanocytes in primates induced bya prostaglandin analogue. Exp Eye Res 1999;69431- 436
PubMed Link to Article
Selen  GStjernschantz  JResul  B Prostoglandin-induced iridial pigmentation in primates. Surv Ophthalmol 1997;41 ((suppl 2)) S125- S128
PubMed Link to Article
Prota  GVincensi  MRMapolitano  ASelen  GStjernschantz  J Latanoprost stimulates eumelanogenesis in iridial melanocytes of cynomolgusmonkeys. Pigment Cell Res 2000;13147- 150
PubMed Link to Article
Zhan  GLToris  CBCamras  CBWang  YLBito  LZ Prostaglandin-induced iris color darkening: an experimental model. Arch Ophthalmol 1998;1161065- 1068
PubMed Link to Article
Grierson  ILee  WRAlbert  DM The fine structure of an iridectomy specimen from a patient with latanoprost-inducedeye color change. Arch Ophthalmol 1999;117394- 396
PubMed Link to Article
Grierson  ICracknell  KPPfeiffer  N The iris after prostanoid treatment. Curr Opin Ophthalmol 2001;12112- 118
PubMed Link to Article
Pfeiffer  NGrierson  IGoldsmith  HHochgesand  DWinkgen-Bohres  AAppleton  P Histological effects in the iris after 3 months of latanoprost therapy:the Mainz 1 study. Arch Ophthalmol 2001;119191- 196
PubMed
De Asua  LJClingan  DRudland  PS Initiation of cell proliferation in culture mouse fibroblasts by prostaglandinF2alpha. Proc Natl Acad Sci U S A 1975;722724- 2728
PubMed Link to Article
Black  FMWakelam  MJ Activation of inositol phospholipid breakdown by prostaglandin F2 alphawithout any stimulation of proliferation in quiescent NIH-3T3 fibroblasts. Biochem J 1990;266661- 667
PubMed
Conconi  MTSpinazzi  RTommasini  MLimoli  AParnigotto  PP Prostaglandin F2 alpha can modulate the growth and the differentiationof bovine corneal epithelial cells cultured in vitro. Ann Anat 2001;183567- 573
PubMed Link to Article

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 15

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections